SJCAR19
/ St. Jude Children's Research Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 19, 2025
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1/2 | N=24 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Jul 2025 ➔ Jul 2026
Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics
October 30, 2024
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1/2 | N=24 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Jul 2024 ➔ Jul 2025
Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics
August 23, 2023
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1/2 | N=26 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Recruiting ➔ Active, not recruiting
Enrollment closed • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics
March 17, 2023
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1/2 | N=35 | Recruiting | Sponsor: St. Jude Children's Research Hospital | Active, not recruiting ➔ Recruiting
Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19
1 to 4
Of
4
Go to page
1